Caffeine in the Treatment of Atopic Dermatitis and Psoriasis: A Review

Mais Alashqar, MD¹, Norman Goldstein, MD²

¹Alfaisal University, Riyadh, Saudi Arabia
²Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

ABSTRACT

Atopic dermatitis (AD) and psoriasis are inflammatory skin diseases. AD is characterized by immune dysregulation and barrier impairment, while psoriasis is by immune dysfunction and resultant keratinocyte hyperproliferation. Caffeine has shown positive effects on the symptoms of both diseases, but it is not conclusive through which pathways. The aim of this study was to provide a detailed discussion of available work on this topic, as well as known modes of action of caffeine that are relevant to these two conditions. After an extensive review of the literature, we found that both diseases have decreased intracellular cyclic adenosine monophosphate (cAMP) levels in cutaneous leukocytes, so it is very likely that being a methylxanthine, and hence a phosphodiesterase (PDE) inhibitor, caffeine raises intracellular cAMP levels, which suppresses inflammatory pathways and potentiates anti-inflammatory ones. Moreover, caffeine is known to be an ATR (ataxia-telangiectasia mutated) kinase and an ATM (ATM- and Rad3-Related) kinase inhibitor, which promotes prompt apoptosis of damaged cells. It was also found to have anti-necrotic effects in reactive oxygen species (ROS)-damaged cells. These pro-apoptotic and anti-necrotic properties may also be reducing the inflammation. Finally, caffeine’s metabolites have shown antioxidizing effects against ROS, which certainly would reduce inflammation caused by lipid peroxidation, DNA damage and organelle destruction. We find that caffeine acts in a number of ways to improve symptoms of inflammation and that it may be an effective adjunct to therapy in AD and psoriasis.

INTRODUCTION

Atopic dermatitis (AD) and psoriasis are inflammatory, T-cell mediated disorders of the skin. AD presents as erythematous, pruritic papules, exacerbated by xerosis. Its chronic lesions become lichenified, hyperpigmented, and are often excoriated. [1] It usually starts in childhood, but may have an adult onset as well. [2] It was believed that the majority of children affected would outgrow this condition, but recent work in JAMA Dermatology has shown that for most it will be a life-long disorder. [3] Up to 20% of children in the World are affected by AD, and up to 3% of adults, so this disease is one of significant global burden. [4]

Psoriasis presents as well-demarcated macaceous plaques or papules, usually with silver scales. Sometimes it presents with pustules, and many psoriasis patients also have nail and/or joint involvement. Stress and infections usually worsen the symptoms. In a 2014 study, the prevalence of psoriasis in...
adults was reported as 3.2% in the United States.[5]

Topical caffeine has been shown to help both diseases, in a number of trials. Below we review available work on the topic and currently known modes of action of caffeine in inflammatory skin disorders.

### MODELS OF PATHOGENESIS

These diseases are, at their core, idiopathic, but many theories exist to explain the laboratory and clinical findings associated with them.

**Atopic Dermatitis:**

Atopic patients were known to have hypersensitivity to β-adrenergic blockade, which sparked an interest in the possible role of cAMP level abnormalities and β-adrenergic dysregulation in AD. [6] There is a statistically significant decrease in cAMP levels of cutaneous and peripheral blood leukocytes in atopic dermatitis. [6] This decrease may be due to the increased activity of PDE in these cells, as was reported in many studies. [7-11] Normal PDE levels in local and peripheral leukocytes have also been declared. [12, 24]

Despite the mixed results, PDE inhibitors, which raise the intracellular cAMP, remain effective in the treatment of AD. [14-18] One such example is E6005. It is a topical, potent PDE4 inhibitor that has proven to alleviate the pruritic component of AD, by multiple mechanisms: suppressing the proteinase-activated receptor 2 (PAR2) effect (a known possible component of the pruritic pathway [19]) and by raising cAMP levels, which reduces LTB4 production in keratinocytes (also a possible component of the pruritic pathway [20]). [21-23] Forskolin, also a cAMP elevator, has shown to have anti-pruritic properties. [22] Rolipram, Ro 20-1724, and nitraquazone have all been shown to improve AD as well, in a study from 1993. [24] In 2016, two double-blind studies confirmed the efficacy and safety of the use of crisaborole ointment, another PDE4 inhibitor, in the treatment of AD. [14,25]

Higher cAMP levels have been shown to inhibit pro-inflammatory pathways, induce anti-inflammatory pathways, and affect gene expression (through modulation of cAMP response element-binding proteins (CREB)) in leukocytes, keratinocytes, and cutaneous fibroblasts. [6,26] This includes reduced levels of IFN-β, IFN-γ, TNF-α, interleukin 12, inducible nitric oxide (NO) synthase, leukotriene B4, macrophage inflammatory proteins 1α and 1β, and Nuclear Factor-kappaB; while increased production of interleukin 10. [6,26-28]

Theories that attempt to explain AD are many, but there is definitely a component of immune dysregulation and one of poor skin barrier function; yet which ignites the other remains controversial. [1]

The *outside-inside hypothesis* suggests that genetic abnormalities cause a barrier dysfunction, and secondarily dermatitis. For example, FLG gene mutations, affecting the filaggrin protein, impair the integrity of the corneal layer and tight junction mutations affect that of the granular layer of the skin in AD. [1] Both of these mutations can increase the skin’s permeability to allergens, irritants, and infectious agents, that would ignite inflammation.[1]

The *inside-outside hypothesis*, however, suggests the genetic abnormalities cause immune dysregulation first. AD leukocytes
have intrinsically higher levels of cAMP phosphodiesterase, and consequently lower intracellular cAMP and higher IgE production, which suppresses the Th1 immune responses, and promotes a Th2-oriented response, with resultant cytokines and ROS-damage weakening the barrier. [1]

Alternatively, the outside-inside-outside hypothesis suggests that the immune dysfunction and the impaired barrier act simultaneously to form a vicious cycle, both exacerbating one another. An impaired barrier would allow allergens to easily penetrate, and activate the inflammatory process, which being abnormal and exaggerated, would further damage the barricade. [1]

Regardless of the sequence, each component in the inflammatory pathway and the barrier dysfunction involved is a potential target for novel therapy.

Psoriasis:

Psoriasis is a multifactorial disease that remains largely idiopathic. It is known to be autoimmune and inflammatory, with both genetic and environmental triggers and aggravators. [1,29] In fact, 71% of children affected have a family history of psoriasis, as reported by Morris et al. [30]

A vicious cycle exists in predisposed individuals, where an abnormal and inflated immune response to an allergen occurs, with cytokines released actually causing both inflammation, as well as keratinocyte hyper-proliferation; hence the distinctive raised plaques and mica-like scales of psoriasis. [29] The cell cycle of the keratinocytes is also expedited. [31] These keratinocytes produce cytokines, themselves, that attract more leukocytes to the lesion, further propagating the cycle.[29]

In psoriasis, as with AD, the findings include decreased cAMP levels. [32,33] Some studies have countered this, and researchers offered that previously recorded cAMP levels were altered by the biopsying technique, or by the lack of β-adrenergic response and ischemic effect in psoriatic lesions. [34-36] The overwhelming mass of research, however, has recognized the beneficial effects of PDE inhibitors for the treatment of psoriasis. The fact that they raise intracellular cAMP levels supports the initial notion that cAMP levels are decreased in leukocytes of psoriatic lesions. [19]

For example, Apremilast and benzoaxaboroles (particularly crisaborole) are both PDE4 inhibitors, and they have shown great results, diminishing psoriatic lesions and reducing inflammatory cytokine production. [6,38-40,44]

Caffeine has been shown to provide relief to AD patients. [45,46] In 1976, Kaplan et al. conducted a preliminary trial on 20 patients, where they compared the effectiveness of 10% caffeine (in a hydrophilic base) with a placebo, on the following scales: erythema, pruritus, scaling, oozing, lichenification, and overall subjective evaluation. [45] They found a statistically significant improvement in the overall subjective evaluation, so pursued a follow-up study using a caffeine concentration of 30% on 40 AD patients (28 were included in the analysis). [45,46] In the second research, published the year after, Kaplan et al. reported a statistically significant improvement in all scales tested in the caffeine group, while the placebo group showed improvement only in pruritus. [46]
1978, another study on 83 AD patients was published comparing three formulations (all in hydrophilic bases): 0.5% hydrocortisone ointment, caffeine 30% and hydrocortisone 0.5% ointment, and betamethasone valerate 0.1% cream. They noted improvement in all study groups on all scales; however, the caffeine-hydrocortisone group and the betamethasone group were significantly superior to the hydrocortisone group on the scales of excoriation, lichenification, and global impression. Moreover, the caffeine-hydrocortisone and the betamethasone groups did not differ statistically significantly on any scale. [47]

The main side effect of the caffeine preparation was an immediate pruritic or burning sensation, which occurred in 4 out of an original 90 participants selected for the study. This may have been due to the “grittiness” of the caffeine blend, as described by the authors. [47]

Corticosteroids, on the other hand, may cause side effects such as pigment changes, perioral dermatitis, delayed wound healing, and others, making the use of caffeine to enhance the effect of lower concentrations of corticosteroids an attractive option. [47,48]

In another trial, Vali et al tested caffeine 10% (in a plastibase of liquid paraffin and polyethylene) on the plaque psoriasis of 39 patients, versus a placebo. A statistically significant difference was observed, but only after 8 weeks of treatment. One side effect was noted, which was mild pruritus. [49]

Caffeine as a PDE Inhibitor:

Caffeine is a methylxanthine, so is an inhibitor of the PDE enzymes, and hence increases intracellular cAMP levels. As discussed earlier, this has an anti-inflammatory effect, as it counteracts the noted decrease in cAMP levels in AD and psoriasis. In fact, Kaplan et al and Vali et al both associate their findings to this sequence. [45-47,49]

Caffeine as an ATR Kinase Inhibitor:

Generally, when a cell in the body undergoes DNA damage, checkpoint activations are induced and are followed by cell cycle arrest, and then apoptosis or DNA repair. [50,51] The repair process, also known as the DNA damage response (DDR), is a network of interlinked pathways, controlled by the ATM (ataxia-telangiectasia mutated) and ATR (ATM- and Rad3-Related) kinases. While ATM is mainly concerned with double-stranded DNA breaks (DSBs), ATR is activated by many forms of DNA damage, including DSBs.[50,52]

The function of this process is to restore the DNA; however, sometimes the repair is imperfect, and although allows the cell to survive, it causes abnormalities in the cell cycle, potentially leading to malignancy. [50,53] Inhibition of these pathways induces unhazardous cell apoptosis instead. [63, 68]

Many studies have recognized the value of inhibiting ATR and ATM in 1) preventing cancers and 2) in improving therapeutic outcomes. Work by Charrier et al describes the use of aminopyrazines to inhibit ATR, and so allow DNA-damaging chemotherapy to work more effectively, by preventing the cancerous cells from repairing their DNA after this tackle. [64] Pires et al and Fokas et al used the ATR inhibitors VE-821 and VE-822 to successfully improve outcomes of radiotherapy. [55,56]

Caffeine is also a known DNA repair inhibitor, as described by Lehmann and Rauth. [52, 57] Later work describes that gaps formed during DNA replication in the daughter strands were
not repaired if caffeine was present in the medium. [57-60] In fact, caffeine has been used to enhance the cytotoxic effect of radio- and chemotherapy in many trials. Gaudin et al showed that caffeine could re-sensitize Cytoxan-resistant plasmacytomas to the effects of X-rays, nitrogen mustard, and Cytoxan. [61] Rauth et al used it to enhance cytotoxicity to mitomycin c. [62] Sarkaria et al identified caffeine as both an ATR and an ATM inhibitor and noted its ability to increase radiosensitivity of cultured cells. [63]

Zajdela et al conducted two independent experiments on healthy mice ears, where they coated one ear with 0.1% caffeine solution before irradiating both ears with UV light, to find that 89% of uncoated ears developed cutaneous tumors, while only 47%-54% of coated ears did. [64] Upon ROS-induced damage, caffeine was found to reduce necrosis of skin fibroblasts. [65] Moreover, that study reported no statistically significant increase in the number of apoptotic fibroblasts, indicating that the anti-necrotic effect may have been through another unidentified pathway.

What is of interest to us here is that caffeine seems to possess both pro-apoptotic and anti-necrotic properties, which serve to inhibit inflammation caused by external factors. Necrosis causes a sudden release of self-antigens and cell components into the surrounding milieu, which promotes harmful consequent inflammation. [66] At the same time, cells that are damaged beyond repair should be removed instantaneously by apoptosis. Additionally, the inhibition of ATR and ATM has been shown to upregulate IL10 gene expression, and IL-10 is a prominent anti-inflammatory cytokine. [67] These properties may play a role in caffeine’s anti-inflammatory effect on psoriasis and AD.

**Caffeine as an Antioxidant:**

Oxidants are chemical compounds with the ability to damage other particles by acquiring one or more of their electrons; thereby creating a self-propagating, destructive succession of free radicals.

In the setting of a cell, such a sequence occurs commonly, from toxins or UV radiation for example, ionizing compounds. Not only does this cause DNA damage, but also inflammation by lipid peroxidation and other destructive processes. Thankfully, antioxidants are abundant in the body, like glutathione. It is then a balance between the oxidants and the anti-oxidants.

In 2007, a study reported that daily oral caffeine intake reduced the risk of non-melanoma skin cancer by 30%. [68,69] Later reports confirmed this relationship for melanoma as well. [70]

An in vitro study by Chu et al found that crude caffeine had antioxidant activity and cyclooxygenase-2 inhibition. Interestingly they did not find the same effects in pure caffeine. [71]

Other in vitro investigations also record the ability of caffeine to neutralize singlet oxygen and oxygen radicles and to decrease subsequent lipid peroxidation. [72,73]

More recent work has actually identified the caffeine metabolites: 1-methylxanthine, 1-methyl uric acid, and 1,7-dimethyl uric acid as the real facilitators of this antioxidant activity. [74,75] These results support those of the study by Silverberg et al, where the topical caffeine exerted a protective effect against ROS-damage, but not through an antioxidizing effect (there was a time delay in action), presumably because it had not gone...
through the systemic circulation and was not
turned into its metabolites by hepatic
microsomes. [65,76]

Patients with AD are particularly vulnerable to
oxidative stress, as their immune dysfunction
and barrier impairment cause chronic
inflammation. [1] In this already sensitive
environment, any additional oxidative DNA or
organelle damage would directly defect the
physical barrier further, as well as induce
more pro-inflammatory cytokines. [77] Those,
in turn, would produce more ROS and
would exacerbate the pruritus and physical
damage, and the vicious cycle continues.[77]
Tsukahara et al present that children with
acute AD exacerbations had abnormally
elevated markers of oxidative stress,
oxidative DNA damage, and lipid
peroxidation, compared to their healthy
counterparts.[78]

ROS are very likely contributors in the
development of psoriasis, as well, as redox-
sensitive transduction systems are known to
be implicated in its pathogenesis. [79-82]
Additionally, administering antioxidants has
proven useful in the treatment of
psoriasis.[83,84]

This suggests a possible role of caffeine and
its metabolites in the treatment of AD and
psoriasis, through an ROS-related
mechanism.

Caffeine is usually used as the model for
hydrophilic compounds in penetration
studies; hence, much data establishes
caffeine’s skin penetration from work both in
vivo and in vitro. Absorption of this highly
water-soluble compound is unaffected by
skin thickness, and was even shown to
penetrate through hair follicles at higher
speeds than through the inter-follicular
epidermis.[85,86] Delivering this compound
in hydrophilic-lipophilic nanoemulsions, solid
lipid nanoparticles, and the addition of
chemical penetration enhancers all further
heighten its permeation.[87-89]

It is expected that damage of the stratum
corneum, which usually protects the skin,
would cause an increase in permeability.
Work by Rubio et al shows that as skin barrier
impairment increases, the rate of caffeine
absorption increases exponentially. [90] This
is not true for all compounds, as they also
found that the increase in the case of salicylic
acid is only linear.[90] With barrier
dysfunction underpinning the pathogenesis
of AD, these results further promote caffeine
as a potential part of the therapy.[1]

Because we do not fully understand neither
the pathogeneses of these diseases, nor the
thorough pharmacology of this compound,
we are only left to hypothesize on its possible
modes of action in each case; but what we do
know is that it is useful. We know that it is
effective in inhibiting DNA repair and inducing
sound apoptosis of UV-damaged cells. We
know that it can reduce injurious necrosis of
ROS-damaged cells. We know that it can
help reduce inflammation by raising
intracellular cAMP levels of cutaneous and
peripheral leukocytes. Finally, we know that
its metabolites can neutralize oxidants in the
body. All of these effects, combined, may act
to reduce inflammation caused by internal
and external sources, which is particularly
valuable in inflammatory cutaneous disorders
like psoriasis and atopic dermatitis. In fact,
because the vast majority of skin diseases
have at least some degree of inflammation,
we may see caffeine supplementing the
therapy of others in the future. More research is needed to fully elucidate its potential, but so far results are promising.

Caffeine is a cheaper, safer alternative that could complement the long-term therapy of AD and psoriasis patients.

**Conflict of Interest Disclosures:** None.

**Funding:** None.

**Corresponding Author:**
Mais Alashqar, MD
Alfaisal University
Riyadh, Saudi Arabia
maisalashqar@gmail.com

**References:**

in the DNA synthesis phase. Radiation research, 40(2), 414-429.


69. Song, F., Qureshi, A. A., & Han, J. (2012). Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer research, 72(13), 3282-3289.


